Freenome

Freenome (operating under freenome.com) is a high-growth biotechnology and molecular diagnostics company that utilizes a proprietary AI-driven multiomics platform to pioneer non-invasive blood tests for early-stage cancer detection. Founded in 2014, the company shifts the paradigm of cancer screening away from isolated, single-analyte genomic testing. Instead, Freenome's platform integrates cell-free DNA (cfDNA), methylation patterns, genomic fragments, and programmatic protein biomarkers with advanced machine learning models to capture complex tumor signals and systemic immune responses at their earliest, most treatable stages. The company's foundational asset, the SimpleScreen colorectal cancer screening blood test, demonstrated exceptional clinical validation through its massive, prospective PREEMPT CRC clinical trial published in JAMA, meeting major efficacy endpoints for sensitivity and specificity. Capitalizing on this multiomic infrastructure, Freenome is aggressively scaling its diagnostic pipeline into a comprehensive Multi-Cancer Early Detection (MCED) portfolio targeting lung, pancreatic, and other high-mortality malignancies. Freenome has secured monumental, multi-million-dollar strategic commercialization and technology agreements with dominant industry pioneers, including a major global expansion partnership with Roche and an extensive distribution and licensing framework with Exact Sciences. Backed by over $1.4 billion in total funding from premier healthcare, tech, and life sciences institutional investors—including Andreessen Horowitz, Bain Capital Life Sciences, RA Capital, and Perceptive Advisors—Freenome entered into a definitive business combination agreement with Perceptive Capital Solutions Corp in late 2025 to transition into a publicly traded entity on the Nasdaq under the ticker FRNM. Headquartered in Brisbane, California, the organization operates sophisticated, CLIA-certified laboratory facilities and is led by industry veteran Dr. Aaron Elliott as Chief Executive Officer.